This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

For healthcare professionals only

You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.


This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.


This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.

I hereby declare I am a non-US health care professional and that I have read and agreed to the terms mentioned above.

ASCVD in T2D thumbnail

Atherosclerosis is the predominant cause of CVD and death in people with type 2 diabetes. Hence, it is crucial to identify and treat people with type 2 diabetes and long-term atherosclerotic CVD risk early.
Patient engagement platform thumbnail

Comorbid cardiovascular disease and diabetes can raise patient concerns and present particular management challenges. can help answer patient questions, giving you more time to focus on their treatment.
Understanding GLP 1 thumbnail

Learn what GLP-1 is, how it works in the body, and why it is important.

ESC 2024, London, UK

Thank you for attending ESC 2023. Join us again at ESC 2024 on August 30 - September 2, 2024, in London, UK and Online.

Rybelsus thumbnail

RYBELSUS® (semaglutide tablets) is the only GLP-1 RA in a pill, which can deliver HbA1c reduction with the added benefit of weight loss, helping your patients to reduce the risk of long-term complications associated with type 2 diabetes.1-4


RYBELSUS® [summary of product characteristics]. Bagsværd, Denmark: Novo Nordisk A/S; April 2023.


Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA. 2019 Apr 16;321(15):1466-1480.


Rodbard HW, Rosenstock J, Canani LH, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care. 2019 Dec;42(12):2272-2281.


Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019;394(10192):39-50.